Ventris Medical has secured 510(k) clearance from the US Food and Drug Administration (FDA) for its synthetic bone graft putty, Amplify.

This clearance allows the use of Amplify in the intervertebral disc space. It is claimed to be a new class of synthetic biomaterials designed to optimise cell proliferation and bone formation.

It consists of biphasic ceramic granules (HA/βTCP) suspended in an alkylene oxide polymer carrier.

The device is designed to be used standalone or along with autograft bone in a 1:1 ratio as a bone graft extender.

The granules in Amplify undergo a patented surface activation process to enhance remodelling potential.

This process creates a network of polygonal microfilaments that extend from the granule surface, acting as a bio-instructive vector to entrap healing elements and guide cellular processes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The activation increases surface area, porosity, and dissolution rate, which in turn promotes cellular attachment, proliferation, and remodelling.

Amplify’s mineral component is a hybrid mixture of surface-activated biphasic granules with two distinct HA-to-βTCP blends that resorb at different rates.

These granules, with ratios of 20/80 and 60/40, offer a bimodal dissolution profile that supports both early healing and progressive bone remodelling.

The polymer blend in the device offers a cohesive, mouldable matrix that enables accurate graft placement and containment at the defect site.

This polymer is resorbed into the surrounding tissues post-implantation, allowing the activated biphasic granules to exert their healing effects immediately.

Ventris Medical CEO Russell Cook said: “We are very pleased to receive FDA clearance for the Amplify synthetic bone graft putty for the intervertebral disc space. This technology combines two heavily studied biphasic mineral components, which are surface-activated through our patented process and suspended in our proprietary polymer carrier.

“In a market crowded with a plethora of commodity offerings, our company mission is to develop next-generation devices that bring excitement to the surgeon community, as well as our distribution partners.”